Buy Lynparza (olaparib). Lynparza (olaparib) is a drug that blocks a certain enzyme in cancer cells. It is used to treat:
Advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer:
With an abnormal BRCA gene. It is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy.
With an abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. It is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy.
As maintenance treatment, when the cancer has come back. It is used after the cancer has responded to treatment with platinum-based chemotherapy.
With an abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines.
Human epidermal growth factor receptor 2 (HER2)-negative breast cancer with an abnormal inherited BRCA gene, that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have HR-positive disease, you should have been treated with hormonal therapy.
Metastatic pancreatic cancer with an abnormal inherited BRCA gene. It is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy.
Prostate cancer with abnormal genes called homologous recombination repair (HRR genes). It is used when the cancer is metastatic, and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone.
It comes in tablet form, with either 100 mg or 150 mg of olaparib.
How does Lynparza (olaparib) work?
PARP enzymes play a role in fixing DNA in cells. They help with DNA transcription and repair.
In healthy cells, there are other ways to fix DNA that don’t need PARP enzymes. These ways use BRCA1 and BRCA2 proteins. But, cancer cells with BRCA mutations can’t use these ways.
So, when Lynparza blocks PARP enzymes, cancer cells can’t fix their DNA. This leads to the death of cancer cells. Lynparza helps kill cancer cells by blocking this repair mechanism.
BRCA gene mutations are common in some cancers. They occur in about 15 to 20% of ovarian cancer patients. Also, about 20 to 25% of hereditary breast cancers and 5 to 10% of any breast cancer have BRCA mutations.
Normally, BRCA genes help fix damaged DNA. But, mutations in these genes can lead to tumor formation.
Where has Lynparza (olaparib) been approved?
Lynparza (olaparib) has been approved by:
Food and Drug Administration (FDA), USA:
December 19, 2014, with an accelerated approval for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy
August 17, 2017, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy
January 12, 2018, in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
What is Lynparza (olaparib) used for?
Lynparza (olaparib) is used to treat certain types of cancer. It is approved in many countries for different uses. These include:
European Medical Agency (EMA), European Union (January 9, 2015), Therapeutic Goods Administration (TGA), Australia (January 7, 2016), and Medsafe (November 10, 2016):
It helps adult patients with platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. These patients must have responded well to platinum-based chemotherapy.
Health Canada (May 3, 2019)
It is for adult patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. They must have responded well to first-line platinum-based chemotherapy. A BRCA mutation must be confirmed before starting treatment.
It is also for patients with platinum-sensitive relapsed (PSR) BRCAmutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. They must have responded well to platinum-based chemotherapy.
It treats adult patients with deleterious or suspected deleterious germline BRCAmutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Patients must have been treated with chemotherapy before. Germline BRCA mutation must be confirmed before starting treatment.
This medicine has also been approved in Japan for certain indications. It may have been approved in other regions too. If you have a question about its approval in a specific country, feel free to contact our support team. Buy Lynparza (olaparib)
Maintenance therapy is given after the first treatment of cancer. It aims to slow the cancer’s return or extend the life of patients with advanced cancer.
How is Lynparza (olaparib) taken?
The standard dosage of Lynparza (olaparib) capsules is:
400 mg (8 capsules of 50 mg) taken twice daily
Continue treatment until disease progression.
The standard dosage of Lynparza (olaparib) tablets is:
300 mg taken twice daily
Continue treatment until disease progression or unacceptable toxicity.
Complete information about Lynparza (olaparib) dosage and administration can be found in the official prescribing information listed in our resources section.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Lynparza (olaparib)?
Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) occurred in less than 1.5% of patients. Most events were fatal. All patients had potential contributing factors (previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy)
Pneumonitis occurred in less than 1% of patients exposed to Lynparza. Some cases were fatal.
Use in specific populations
Lynparza (olaparib) can harm a fetus if a pregnant woman takes it. It’s important not to use Lynparza during pregnancy. Women should use reliable birth control while taking Lynparza and for a month after stopping it.
It’s also advised not to breastfeed while taking Lynparza. This is to protect the baby’s health. Buy Lynparza (olaparib)
Optimized by Seraphinite Accelerator